Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 (Anti-Shiga Toxin) in Pediatric Patients With Hemolytic Uremic Syndrome Associated With Shiga Toxin-producing Escherichia Coli Infection

Next Previous
Trial Profile

A Phase II Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 (Anti-Shiga Toxin) in Pediatric Patients With Hemolytic Uremic Syndrome Associated With Shiga Toxin-producing Escherichia Coli Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INM 004 (Primary) ; Fab fragments; Polyclonal antibodies
  • Indications Haemolytic uraemic syndrome
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Immunova

Most Recent Events

  • 14 May 2025 Results assessing the safety, pharmacokinetics, and efficacy of INM004 in pediatric patients with STEC-HUS published in the Pediatric Nephrology.
  • 16 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 18 Jul 2023 Planned End Date changed from 15 Jun 2023 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top